IDH2 and acute myeloid leukemia: Mutations in cytosolic and mitochondrial isocitrate dehydrogenases (IDH1 and IDH2), resulting in the production of the oncometabolite 2-hydroxyglutarate, are commonly seen in AML cells, and are frequently targeted for therapy, since they limit cellular differentiation and promote leukemogenesis [22, 23].